SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) Highlighting Recent Uplisting to Nasdaq

NEW YORK, NY / ACCESSWIRE / July 20, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications.

The note is available here: DMPI July 2016 Update.

"DMPI management competed a key strategic goal on the corporate development front, with the company uplisting shares to the Nasdaq Capital Market as of July 12, 2016. CEO of the company, Jeffrey Bacha, rang the NASDAQ's opening bell on July 14, 2016. We see the move as a major milestone for the company and a significant accomplishment by management, reflecting the measurable progress by the company over the last several years. As part of the uplisting process, DelMar completed a capital raise to ensure the company would meet shareholders' equity requirements, and a 1 to 4 reverse stock split in order to meet the minimum bid requirement to list shares on the NASDAQ. Additionally, the uplisting to the NASDAQ should serve to raise DMPI's prestige in the industry while improving share liquidity and allow access to potential institutional investors who could not invest in OTC shares," commented Ajay Tandon, CEO of SeeThruEquity. "We are adjusting our price target for DMPI to $19.20 from the prior target of $5.75, reflecting the new share count and the 1 to 4 reverse split."

Additional highlights from the update note are as follows:

DMPI lists on Nasdaq Capital Market

DMPI management competed a key strategic goal on the corporate development front, with the company uplisting shares to the Nasdaq Capital Market as of July 12, 2016. We see the move as a significant accomplishment by management, which should serve to raise DMPI's prestige in the industry while improving share liquidity and allowing DMPI access to potential institutional investors who could not invest in OTC shares.

Financing eases liquidity pressures

In May, DelMar completed a private placement in which the company raised a $6.1mn in gross proceeds ($5.6mn net), through the issuance of preferred stock. We believe the raise was a part of the company's efforts to uplist to the Nasdaq (as was a 1:4 reverse stock split). As part of the transaction, DMPI restructured 72% of investor warrants in order to reduce its derivative liability. DMPI management now estimates that it has approximately $10mn of potential additional funding from in-the-money warrants. Considering the financing and potential warrant exercises, management believes it has sufficient funding to last through 2017.

DelMar continues to advance its clinical program

In addition to the corporate initiatives completed over the last seral months, DMPI continues to advance its clinical program.The company had a successful presentation of Phase 1/ Phase 2 data from its VAL-083 GBM clinical trials to key figures in the global cancer research community at the cancer at the American Society of Clinical Oncology's (ASCO) Annual Meeting in June, and has outlined plans for a Phase 3 clinical trial for VAL-083 for refractory GBM and another two Phase 2 trials for GBM in earlier stage patients.

Adjusting price target to $19.20

We are adjusting our price target for DMPI to $19.20 from the prior target of $5.75, reflecting the new share count and the 1:4 reverse split. In our view it is clear that DMPI is making significant progress advancing its clinical pipeline, with VAL-083 having potential to address a number of therapeutic indications. Management continues to execute on a number of fronts, from securing financing and listing shares on the Nasdaq CM to advancing its clinical pipeline and expanding the number of potential indications that could be addressed by VAL-083. If achieved, the price target represents potential upside of 106.5% from the recent price of $9.40 on July 12, 2016.

Please review important disclosures at www.seethruequity.com.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerant to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit www.delmarpharma.com; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City. For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 442599

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.